Metsa 850 mg Tablet

Metsa 850 mg Tablet — Metformin Hydrochloride

Overview

Metsa 850 mg Tablet provides an intermediate metformin strength for patients who need a higher per-tablet dose than 500 mg but do not require the simplified once-daily extended-release option. Manufactured by Synovia Pharma PLC., it offers a cost-effective way to reach standard maintenance doses with fewer tablets per administration.

Mechanism of Action

Metformin reduces blood glucose by lowering hepatic gluconeogenesis, reducing intestinal glucose absorption, and improving insulin sensitivity in peripheral tissues such as skeletal muscle. Because it does not directly stimulate insulin secretion, the risk of hypoglycemia is low when metformin is used as monotherapy.

Indications

Metsa 850 mg is indicated for type 2 diabetes mellitus in patients requiring a higher metformin dose per tablet, typically after demonstrating tolerance to lower doses. It may be used alone or in combination with other oral antidiabetic agents or insulin under medical supervision.

Dosage and Administration

A typical regimen is 850 mg once daily with a meal, which may be increased to twice daily after 1–2 weeks if tolerated and clinically indicated, up to a generally accepted maximum of around 2550 mg/day across all metformin-containing products. Taking the tablet with food reduces gastrointestinal upset. Dose adjustments should always follow physician guidance.

Contraindications

Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²), metabolic acidosis including diabetic ketoacidosis, and known hypersensitivity to metformin. Caution advised in hepatic impairment and conditions predisposing to tissue hypoxia or volume depletion.

Side Effects

Gastrointestinal symptoms such as nausea, diarrhea, and abdominal discomfort are the most common adverse effects, particularly when stepping up from a lower dose; gradual titration and taking the tablet with food help minimize these effects. Long-term use may be associated with reduced vitamin B12 absorption. Lactic acidosis is rare and occurs mainly in patients with underlying renal or hepatic disease.

Drug Interactions

Concurrent use of iodinated contrast agents requires temporary discontinuation of metformin due to the risk of acute kidney injury and lactic acidosis. Excessive alcohol consumption should be avoided. Disclose all current medications and supplements to your prescribing physician or pharmacist.

Special Precautions

Renal function should be assessed prior to initiation and monitored periodically, especially in older adults. Temporary discontinuation is advised during acute illness involving dehydration, vomiting, or significant reduction in oxygen delivery to tissues.

Storage

Store below 30°C in a dry place away from direct sunlight. Keep out of reach of children.

Frequently Asked Questions

Q1: How is Metsa 850 different from Metsa 500?
Metsa 850 contains a higher dose of metformin per tablet, allowing patients who need higher total daily doses to take fewer tablets; the active ingredient and mechanism are identical.

Q2: Can I take Metsa 850 twice daily from the start?
Most physicians recommend starting with once-daily dosing and increasing gradually to twice daily based on tolerance and blood glucose response, rather than starting at the higher frequency immediately.

Q3: What if I experience persistent diarrhea with Metsa 850?
Persistent gastrointestinal symptoms should be reported to your physician, who may adjust the dose, suggest taking it with more food, or consider an extended-release formulation.

Q4: Is Metsa 850 suitable during Ramadan fasting?
Patients who fast should discuss dose timing adjustments with their physician in advance, as metformin dosing schedules may need modification during prolonged fasting periods.

Medical Disclaimer: This information is provided for educational purposes only and does not replace professional medical advice. Always consult a registered physician or pharmacist before starting, stopping, or changing any medication. Dosage and suitability vary by individual health condition.